Lymph nodes and Peyer's patches of Il-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain μ locus and c-myc

Leukemia

Volumn 14, Issue 6, 2000, Pages 1127-1135

  Kovalchuk, A L ^a   Kishimoto, T ^b   Janz, S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Chromosomal translocation; Plasmacytomagenesis; Tumor precursor

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 6; PRISTANE; SILICONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CLONE; CELL GROWTH; CELL SURVIVAL; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 15; CONTROLLED STUDY; DNA FLANKING REGION; GENE REARRANGEMENT; GENETIC RECOMBINATION; GRANULOMATOSIS; LYMPH NODE; MOUSE STRAIN; NONHUMAN; ONCOGENE C MYC; PERITONEUM TUMOR; PEYER PATCH; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; STEM CELL; TRANSGENIC MOUSE; TUMOR CELL;

EID: 0034081363     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401767     Document Type: Article

References (34)

1. Kovalchuk AL, Müller JR, Janz S. Deletional remodeling of c-myc-deregulating translocations. Oncogene 1997; 15: 2369-2377.
2. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1992; 89: 232-235.
3. Müller JR, Potter M, Janz S. Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells. Proc Natl Acad Sci USA 1994; 91: 12066-12070.
4. Müller JR, Jones GM, Janz S, Potter M. Migration of cells with immunoglobulin/c-myc recombinations in lymphoid tissues of mice. Blood 1997; 89: 291-296.
5. Müller JR, Jones GM, Potter M, Janz S. Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction. Cancer Res 1996; 56: 419-423.
6. Kovalchuk AL, Potter M, Janz S. DNA sequence analysis of the genetic recombination hetween Igh6 and Myc in an uncommon BALB/c plasmacytoma, TEPC 1194. Immunogenetics 1996; 44: 151-156.
7. Ohno S, Hayakawa J, Hashimoto N, Wiener F. Murine plasmacytomas, carrier of the td(12;15) chromosomal translocation, develop from immature/mature B cells not from differentiated plasma cells. Carcinogenesis 1999; 20: 529-538.
8. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromsome translocation. Adv Cancer Res 1986; 47: 189-234.
9. Yang JQ, Bauer SR, Mushinski JF, Marcu KB. Chromosome translocations clustered 5′ of the murine c-myc gene qualitatively affect promoter usage: implications for the site of normal c-myc regulation. EMBO J 1985; 4: 1441-1447.
10. Fahrlander PD, Sumegi J, Yang JQ, Wiener F, Marcu KB, Klein G. Activation of the c-myc oncogene by the immunoglobulin heavy-chain gene enhancer after multiple switch region-mediated chromosome rearrangements in a murine plasmacytoma. Proc Natl Acad Sci USA 1985; 82: 3746-3750.
11. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
12. Dunnick W, Hertz GZ, Scappino L, Gritzmacher C. DNA sequences at immunoglobulin switch region recombination sites. Nucleic Acids Res 1993; 21: 365-372.
13. Gutierrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas ML, Epelman S, Risueno C, Magrath IT. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 1992; 79: 3261-3266.
14. Dunnick W, Wilson M, Stavnezer J. Mutations, duplication, and deletion of recombined switch regions suggest a role for DNA replication in the immunoglobulin heavy-chain switch. Mol Cell Biol 1989; 9: 1850-1856.
15. Radbruch A, Burger C, Klein S, Muller W. Control of immunoglobulin class switch recombination. Immunol Rev 1986; 89: 69-83.
16. Ohki R, Hirota M, Oishi M, Kiyama R. Conservation and continuity of periodic bent DNA in genomic rearrangements between the c-myc and immunoglobulin heavy chain mu loci. Nucleic Acids Res 1998; 26: 3026-3033.
17. Cerutti A, Zan H, Schaffet A, Bergsagel L, Harindranath N, Max EE, Casali P. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+B cell line. J Immunol 1998; 160: 2145-2157.
18. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999; 189: 63-73.
19. Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996; 93: 4885-4890.
20. Shacter E, Arzadon GK, Williams J. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood 1992; 80: 194-202.
21. Potter M, MacCardle RC. Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice. J Natl Cancer Inst 1964; 33: 497-515.
22. Potter M, Wax J, Jones GM. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. Blood 1997; 90: 260-269.
23. Byrd LG, McDonald AH, Gold LG, Potter M. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane. J Immunol 1991; 147: 3632-3637.
24. Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233: 566-569.
25. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 1993; 90: 2060-2064.
26. Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donckers D, Van Snick J. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med 1990; 172: 997-1000.
27. Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, Poli V. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997; 151: 689-696.
28. Hubert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995; 182: 243-248.
29. Largaespada DA, Kaehler DA, Mishak H, Weissinger E, Potter M, Mushinski JF, Risser R. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene 1992; 7: 811-819.
30. Weissinger EM, Byrd LG, Henderson DW, Mushinski JF. Overexpression of v-abl uniquely cooperates with c-myc dysregulation in induction of plasma cell tumors, bypassing the need for T-lymphocytic help and overcoming T-lymphocytic interference. Int J Cancer 1996; 67: 142-147.
31. Hilbert DM, Migone TS, Kopf M, Leonard WJ, Rudikoff S. Distinct tumorigenic potential of abl and rat in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity 1996; 5: 81-89.
32. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. IgGl plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989; 86: 7547-7551.
33. Madisen L, Groudine M. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev 1994; 8: 2212-2226.
34. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18: 2967-2987.